



## Corporate Profile

CytomX Therapeutics develops Probody™ therapeutics for the treatment of cancer. Probody therapeutics are fully recombinant masked antibodies that remain inert in healthy tissue but are activated specifically in the disease microenvironment. The Probody approach is designed to blunt systemic toxicities associated with antibodies and expand the therapeutic window of these drugs, potentially unlocking new therapeutic targets. The Company is initially focusing this highly innovative platform to discover and develop new immunotherapy and antibody drug conjugate therapies to treat areas of major unmet medical need in oncology.

## Stock Performance

### CTMX (Common Stock)

Exchange	NASDAQ CM (US Dollar)
Financial Status Indicator	C
Price	<b>\$14.45</b>
Change (%)	<b>▼ 0.45 (3.02%)</b>
Volume	170,253
52 Week Low	\$9.16
Market Cap	\$547,571,007
Rolling EPS	-1.41
PE Ratio	0
Shares Outstanding	36,749,732

Data as of 06/27/17 4:00 p.m. ET



## Recent Headlines

05/25/17

CytomX to Present at the Jefferies 2017 Global Healthcare Conference

05/17/17

CytomX Announces Upcoming Poster Presentation at American Society for Clinical Oncology Annual Meeting

05/15/17

CytomX Announces Management Team Changes

## Upcoming Events

There are currently no events scheduled.

## SEC Filings

Filing Date	Form	Description
06/27/17	4	Statement of changes in beneficial ownership of securities
06/27/17	4	Statement of changes in beneficial ownership of securities
06/22/17	4	Statement of changes in beneficial ownership of securities
06/22/17	4	Statement of changes in beneficial ownership of securities

Data provided by Nasdaq. Minimum 15 minutes delayed.